Despite Asia Pacific being one of the fastest growing pharmaceutical markets in the world, the region has historically faced major real-world evidence data gaps: These have traditionally been due to the resource-driven limitations across this fragmented market; the result being sizeable challenges to data collection using traditional research methods and leaving many key questions unanswered.
In this webinar, we examine the role of the HCC Analyzer in addressing the unmet needs in the diagnosis, treatment and clinical outcomes associated with HCC in Asia Pacific, and its focus on delivering data from a patient-centric approach at a more cost-effective way. The HCC Analyzer sets the tone for syndicated registries in the region and provides HCC patients with a voice in the era of big data by evaluating:
- Patient health-related quality of life (HRQoL) via Patient Reported Outcomes (PRO)
- Healthcare resource utilization (HCRU)
- Direct and indirect costs associated with HCC treatment
Join Yvanka Gilliam, PharmD, Principal, Strategy/Life Sciences, IQVIA Asia Pacific for a discussion on the tailored approach of the HCC Analyzer as a vital data source in Asia Pacific to generate real-world insights for better patient outcomes and decision making.